ChromaDex, Inc. Release: University Researchers Show Vitamin Nicotinamide Riboside Is An Effective Tool For Managing The Negative Effects Of Obesity And Diabetes
IRVINE, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that researchers from the University of Iowa found a way to reduce the risks of developing insulin resistance and sensory neuropathy (nerve damage) in mice with induced prediabetes and type 2 diabetes, using ChromaDex’s nicotinamide riboside (NR), NIAGEN®, which is a form of vitamin B3. The results of this study, published in the journal Scientific Reports, demonstrate that NR was successful at reducing fasting and non-fasting blood glucose levels, as well as weight gain, and was protective against sensory neuropathy in these groups.
“Prevention remains extremely important. This means maintaining a healthy level of physical activity and not overdoing calorie intake,” comments the study’s chief investigator and discoverer of nicotinamide riboside, Charles Brenner, PhD, professor and Roy J. Carver Chair of Biochemistry at the UI Carver College of Medicine and member of the ChromaDex Scientific Advisory Board, “But there are millions of people who are struggling with obesity as well as pre-diabetic and diabetic conditions. This research provides hope that we are on track to find potentially safe and effective nutritional approaches to improving whole-body metabolism, and protecting nerves from diabetic damage.”
In February 2016, ChromaDex announced the commencement of an obesity and diabetes collaborative human clinical study of NR with Dr. Jonas Treebak at the University of Copenhagen, which they hope will leverage and build upon Brenner’s findings.
NR- A Promising Vitamin
NR works by boosting NAD+, the essential metabolite required for cellular energy production. Aging, a sedentary lifestyle, and overeating can cause a decline in NAD+ levels which negatively impacts the efficiency and function of our mitochondria, the energy-producing powerhouses in every cell of our body.
Frank Jaksch, Jr., CEO and co-founder of ChromaDex, the supplier of the first and only commercially available form of NR, sold under the brand name NIAGEN® confirms, “NAD+ depletion is a nutrient deficiency story associated with the aging process which is why it is getting an unprecedented amount of attention in the research community. Over the past few years, there have been a tremendous number of high profile peer reviewed publications demonstrating the effectiveness of NR at boosting NAD+, and positively impacting aging and age related disease,” Jaksch stated.
Last month, a team headed by Dr. Johan Auwerx at EPFL in Switzerland, published a study in Science showing that mice taking NR lived longer than mice that did not. ChromaDex has signed over 67 collaborative agreements for research with universities globally since they launched NR in 2013. “Many of these studies are now publishing. NR is at a tipping point where the body of scientific evidence is too rich to ignore,” Jaksch commented.
Additional scientific research about NR can be found at www.ChromaDex.com. Supplements containing NIAGEN® can be found in products online and on the shelves of select retailers.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® cocrystal; ProC3G®, a natural black rice containing cyanidin-3-glucoside; IMMULINA®, a spirulina extract; and Purple Corn derived from a proprietary non-GMO purple corn hybrid which contains an extraordinarily high level of anthocyanins. To learn more about ChromaDex, please visit www.ChromaDex.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016, the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
ChromaDex Media Contact: Breah Ostendorf, Marketing Director 949-537-4103 BreahO@chromadex.com ChromaDex Investor Contact: Andrew Johnson Director of Investor Relations 949-419-0288 firstname.lastname@example.org